We are very happy to have contributed data to this is a very important publication in The Lancet showing the importance of therapeutically preserving endogenous insulin producing capacity measured as C-peptide in individuals with new-onset type 1 diabetes. The findings show that improvements in metabolic control measured as HbA1c are directly proportional to the degree of C-peptide preservation. 👇 https://lnkd.in/ecrkGviF This is in line with our own published analyses (Journal of Clinical Endocrinology and Metabolism in 2022, Nowak et al) from the DIAGNODE-2 trial showing how C-peptide preservation with the antigen-specific immunotherapy #Diamyd improves time-in-range, reduces glycemic variability and reduces time above range in new-onset T1D individuals carrying the HLA DR3-DQ2 haplotype. Also, a published retrospective metanalysis in individual-level data from four placebo-controlled clinical trials evaluating Diamyd in type 1 diabetes (Diabetes, Obesity and Metabolism in 2022, Nowak et al) shows a clear correlation between therapeutically preserved C-peptide and improvements in HbA1c. #precisionmedicine #cpeptide #immunotherapy #t1d #hba1c #timeinrange #tir #cgm
C-suite Consultant - Rare Disease | C-Suite Consultant Neurology, Immune Mediated at Atlas Ventures | Roivant | Sofinnova | NEA | RA Cap | EU Mid-Cap Clients
11moWhen I see a series of graphs like this, I cringe!